Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.